文献速递临床免疫质量管理与危急值

甲状腺自身抗体免疫分析平台间变异:分析一致性与抗体阳性率的影响

Inter-platform variability of TgAb, TPOAb and TRAb immunoassays: analytical agreement and consequences for antibody positivity.
PubMed 文献 · Clin Chem Lab Med · 2026-10-28

本研究比较四种化学发光免疫分析平台检测742份血清样本中TgAb、TPOAb和TRAb结果的一致性,并评估平台变异对不同临床人群阳性率的影响。结果显示TgAb和TPOAb平台间变异显著,阳性率不一致,而TRAb在Graves病中阳性率一致较高(89.81-98.15%)。平台依赖性差异可能影响甲状腺自身抗体结果的解读,强调需要检测协调化。

要点

  • TgAb和TPOAb在四种平台间变异显著,阳性率不一致。
  • TRAb在Graves病中阳性率一致较高(89.81-98.15%)。
  • 平台差异可能影响甲状腺自身抗体结果的临床解读。

核心结论

  • 甲状腺自身抗体检测存在平台间变异,尤其TgAb,导致阳性率不一致。
  • 平台依赖性差异可能影响结果解读,需要检测协调化。

研究设计与样本

  • 使用四种化学发光免疫分析平台(Roche e 601、Mindray CL-8000i、Abbott Alinity i、Snibe MAGLUMI X3)检测TgAb、TPOAb和TRAb。

主要发现

  • Passing-Bablok回归显示平台间比例差异,TgAb斜率0.1935至2.8455,TPOAb 0.6486至2.1930,TRAb 0.7918至1.2698。
  • Bland-Altman分析显示TgAb和TPOAb的一致性界限宽。
  • TgAb和TPOAb阳性率在自身免疫性甲状腺炎中最高,但所有疾病组平台间变异显著(Cochran's Q,p<0.001)。
  • TRAb在Graves病中阳性率89.81-98.15%,其他组3.00-15.18%,平台间一致性相对较好。

临床怎么用

  • 临床解读甲状腺自身抗体结果时应考虑平台差异。
  • 建议在相同平台进行随访检测以减少变异影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the agreement of anti-thyroglobulin (TgAb), anti-thyroid peroxidase (TPOAb), and thyrotropin receptor antibody (TRAb) results across four automated immunoassay platforms, and to assess the impact of assay variability on positivity rates in different clinical populations. METHODS: A total of 742 serum samples were collected from Shanghai Seventh People's Hospital between September and December 2025. TgAb, TPOAb, and TRAb levels were measured using four chemiluminescence immunoassay platforms (Roche e 601, Mindray CL-8000i, Abbott Alinity i, and Snibe MAGLUMI X3). RESULTS: Significant inter-assay variability was observed. Passing-Bablok regression demonstrated proportional differences among platforms, with slopes ranging from 0.1935 to 2.8455 for TgAb, 0.6486 to 2.1930 for TPOAb, and 0.7918 to 1.2698 for TRAb. Bland-Altman analysis revealed wide limits of agreement, particularly for TgAb and TPOAb. TgAb and TPOAb positivity rates were highest in autoimmune thyroiditis, but showed marked inter-platform variation across all disease groups (Cochran's Q, p<0.001). TRAb positivity was consistently high in Graves' disease (89.81-98.15 %) and low in other groups (3.00-15.18 %), with relatively better agreement across platforms. CONCLUSIONS: Inter-assay variability exists in thyroid autoantibody measurements, particularly for TgAb, leading to inconsistent positivity rates. Platform-dependent differences may influence interpretation of thyroid autoantibody results and emphasize the need for assay harmonization.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. You Q, Sun Y, Wang G, et al. Inter-platform variability of TgAb, TPOAb and TRAb immunoassays: analytical agreement and consequences for antibody positivity. Clin Chem Lab Med. 2026. PMID: 42935447. doi:10.1515/cclm-2026-1197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。